This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Zoetis (ZTS) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Zoetis (ZTS) closed at $182.42, indicating a +1.32% shift from the previous trading day.
Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Zoetis (ZTS) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the second quarter of 2024 in both the United States and International segments.
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Zoetis (ZTS) reachead $179.84 at the closing of the latest trading day, reflecting a -0.51% change compared to its last close.
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
USNA or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
USNA vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
USNA vs. ZTS: Which Stock Is the Better Value Option?
Is Trending Stock Zoetis Inc. (ZTS) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Zoetis (ZTS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 2.99% and 2.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unveiling Zoetis (ZTS) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
Wall Street Analysts Look Bullish on Zoetis (ZTS): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Zoetis (ZTS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day.
Zoetis (ZTS) Stock Moves -0.14%: What You Should Know
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $149.77, marking a -0.14% move from the previous day.
Company News for Apr 15, 2024
by Zacks Equity Research
Companies In The Article Are:INTC,ZTS,X,NPSCY and PGR